Longitudinal impact of smoking and smoking cessation on inflammatory markers of cardiovascular disease risk

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 37, Issue 2, 2017, Pages 374-379

  King, Cecile C ^a   Piper, Megan E ^a   Gepner, Adam D ^a   Fiore, Michael C ^a   Baker, Timothy B ^a   Stein, James H ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

carbon monoxide; cardiovascular diseases; inflammation; oxidative stress; smoking

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CARBON MONOXIDE; CREATININE; D DIMER; FIBRINOGEN; ISOPROSTANE DERIVATIVE; MYELOPEROXIDASE; AUTACOID; PEROXIDASE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; FEMALE; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; LEUKOCYTE COUNT; LONGITUDINAL STUDY; MALE; MIDDLE AGED; PREDICTION; PRIORITY JOURNAL; SMOKING; SMOKING CESSATION; ADOLESCENT; ADVERSE EFFECTS; AGED; BLOOD; CARDIOVASCULAR DISEASES; COMPARATIVE EFFECTIVENESS; INFLAMMATION; OXIDATIVE STRESS; PREVENTION AND CONTROL; PROCEDURES; PROTECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; TIME FACTOR; URINE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; CARDIOVASCULAR DISEASES; COMPARATIVE EFFECTIVENESS RESEARCH; CREATININE; F2-ISOPROSTANES; FEMALE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; LEUKOCYTE COUNT; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OXIDATIVE STRESS; PEROXIDASE; PROTECTIVE FACTORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; RISK REDUCTION BEHAVIOR; SMOKING; SMOKING CESSATION; TIME FACTORS; YOUNG ADULT;

EID: 85004001468     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.116.308728     Document Type: Article

References (37)

1. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937-952. doi: 10.1016/S0140-6736(04)17018-9.
2. The Health Consequences of Smoking-50 Years of Progress: A Report of the Surgeon General. Atlanta, GA, 2014
3. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA. 2003;290:86-97. doi: 10.1001/jama.290.1.86.
4. Jha P, Ramasundarahettige C, Landsman V, Rostron B, Thun M, Anderson RN, McAfee T, Peto R. 21st-century hazards of smoking and benefits of cessation in the United States. N Engl J Med. 2013;368:341-350. doi: 10.1056/NEJMsa1211128.
5. Johnson HM, Gossett LK, Piper ME, Aeschlimann SE, Korcarz CE, Baker TB, Fiore MC, Stein JH. Effects of smoking and smoking cessation on endothelial function: 1-year outcomes from a randomized clinical trial. J Am Coll Cardiol. 2010;55:1988-1995. doi: 10.1016/j.jacc.2010.03.002.
6. Rosenberg L, Palmer JR, Shapiro S. Decline in the risk of myocardial infarction among women who stop smoking. N Engl J Med. 1990;322:213-217. doi: 10.1056/NEJM199001253220401.
7. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809. doi: 10.1038/362801a0.
8. Glass CK, Witztum JL. Atherosclerosis. the road ahead. Cell. 2001;104:503-516.
9. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-1143.
10. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA. 1998;279:1477-1482.
11. Miller M, Zhan M, Havas S. High attributable risk of elevated C-reactive protein level to conventional coronary heart disease risk factors: the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2005;165:2063-2068. doi: 10.1001/archinte.165.18.2063.
12. Mendall MA, Strachan DP, Butland BK, Ballam L, Morris J, Sweetnam PM, Elwood PC. C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J. 2000;21:1584-1590. doi: 10.1053/euhj.1999.1982.
13. Yarnell JW, Baker IA, Sweetnam PM, Bainton D, O'Brien JR, Whitehead PJ, Elwood PC. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell collaborative heart disease studies. Circulation. 1991;83:836-844.
14. Wilhelmsen L, Svärdsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med. 1984;311:501-505. doi: 10.1056/NEJM198408233110804.
15. Stone MC, Thorp JM. Plasma fibrinogen-a major coronary risk factor. J R Coll Gen Pract. 1985;35:565-569.
16. Schwedhelm E, Bartling A, Lenzen H, Tsikas D, Maas R, Brümmer J, Gutzki FM, Berger J, Frölich JC, Böger RH. Urinary 8-iso-prostaglandin F2alpha as a risk marker in patients with coronary heart disease: a matched case-control study. Circulation. 2004;109:843-848. doi: 10.1161/01. CIR.0000116761.93647.30.
17. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol. 2004;43:1731-1737. doi: 10.1016/j.jacc.2003.12.047.
18. Yasue H, Hirai N, Mizuno Y, Harada E, Itoh T, Yoshimura M, Kugiyama K, Ogawa H. Low-grade inflammation, thrombogenicity, and atherogenic lipid profile in cigarette smokers. Circ J. 2006;70:8-13.
19. Wannamethee SG, Lowe GD, Shaper AG, Rumley A, Lennon L, Whincup PH. Associations between cigarette smoking, pipe/cigar smoking, and smoking cessation, and haemostatic and inflammatory markers for cardiovascular disease. Eur Heart J. 2005;26:1765-1773. doi: 10.1093/eurheartj/ehi183.
20. Asthana A, Johnson HM, Piper ME, Fiore MC, Baker TB, Stein JH. Effects of smoking intensity and cessation on inflammatory markers in a large cohort of active smokers. Am Heart J. 2010;160:458-463. doi: 10.1016/j.ahj.2010.06.006.
21. Morrow JD, Roberts LJ. The isoprostanes: unique bioactive products of lipid peroxidation. Prog Lipid Res. 1997;36:1-21.
22. Reilly M, Delanty N, Lawson JA, FitzGerald GA. Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation. 1996;94:19-25.
23. Aldaham S, Foote JA, Chow HH, Hakim IA. Smoking status effect on inflammatory markers in a randomized trial of current and former heavy smokers. Int J Inflam. 2015;2015:439396. doi: 10.1155/2015/439396.
24. Gossett LK, Johnson HM, Piper ME, Fiore MC, Baker TB, Stein JH. Smoking intensity and lipoprotein abnormalities in active smokers. J Clin Lipidol. 2009;3:372-378. doi: 10.1016/j.jacl.2009.10.008.
25. Bazzano LA, He J, Muntner P, Vupputuri S, Whelton PK. Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States. Ann Intern Med. 2003;138:891-897.
26. Hastie CE, Haw S, Pell JP. Impact of smoking cessation and lifetime exposure on C-reactive protein. Nicotine Tob Res. 2008;10:637-642. doi: 10.1080/14622200801978722.
27. Taylor AW, Bruno RS, Traber MG. Women and smokers have elevated urinary F(2)-isoprostane metabolites: a novel extraction and LC-MS methodology. Lipids. 2008;43:925-936. doi: 10.1007/s11745-008-3222-1.
28. Jamal A, Homa DM, O'Connor E, Babb SD, Caraballo RS, Singh T, Hu SS, King BA. Current cigarette smoking among adults-United States, 2005-2014. MMWR Morb Mortal Wkly Rep. 2015;64:1233-1240. doi: 10.15585/mmwr.mm6444a2.
29. Krukowski RA, Bursac Z, Little MA, Klesges RC. The Relationship between Body Mass Index and Post-Cessation Weight Gain in the Year after Quitting Smoking: A Cross-Sectional Study. PLoS One. 2016;11:e0151290. doi: 10.1371/journal.pone.0151290.
30. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003;107:391-397.
31. Festa A, D'Agostino R Jr, Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102:42-47.
32. Hansen LK, Grimm RH Jr, Neaton JD. The relationship of white blood cell count to other cardiovascular risk factors. Int J Epidemiol. 1990;19:881-888.
33. Patrono C, FitzGerald GA. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscler Thromb Vasc Biol. 1997;17:2309-2315.
34. Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H. Role of oxidative stress in atherosclerosis. Am J Cardiol. 2003;91(3A):7A-11A.
35. Zhang R, Brennan ML, Fu X, Aviles RJ, Pearce GL, Penn MS, Topol EJ, Sprecher DL, Hazen SL. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA. 2001;286:2136-2142.
36. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR; Varenicline Phase 3 Study Group. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296:47-55. doi: 10.1001/ jama.296.1.47.
37. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR; Varenicline Phase 3 Study Group. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296:56-63. doi: 10.1001/jama.296.1.56.